Y. Wang

519 Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): Results of a phase 3 Chinese study (ETV-023) in nucleoside-naïve patients

H. Ren, G. Yao, D. Tan, 2006 .

Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real‐world’ clinical practice setting in China

M. Cheng, J. Hou, C. Llamoso, 2013, Journal of viral hepatitis.

Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside‐naive Chinese chronic hepatitis B patients

Xiaoping Zhou, H. Ren, G. Yao, 2010, Journal of viral hepatitis.

[53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS

P. Marcellin, C. Yurdaydın, P. Farci, 2007 .

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.

H. Huang, M. Ding, S. Tao, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[497] TWO-YEAR RESULTS OF A PHASE III COMPARATIVE TRIAL OF TELBIVUDINE VS LAMIVUDINE IN CHINESE PATIENTS

J. Niu, L. Zhu, J. Jia, 2007 .